NORTHLAND

NORTHLAND

Language

The last subject in the Phase III clinical trial of NL003 for the ulcer indication in severe lower-limb ischemic disease has been discharged from the study.

发布时间：2023-12-13

Recently, the last subject has been discharged from the Phase III clinical trial of our company’s “Recombinant Human Hepatocyte Growth Factor Naked Plasmid Injection” (code name NL003), which is intended for the treatment of ischemic ulcers. This marks the completion of more than four years of subject enrollment and follow-up activities for the trial, officially ushering in the data cleaning and statistical analysis phase. The countdown to the release of the final results has now begun.

27

2023-11

The Phase III clinical trial for the indication of resting pain has reached its pre-specified enrollment target, marking significant progress in the NL003 project.

发布时间：2023-11-27

On November 24, 2023, our company completed the enrollment of the target 300 subjects for the Phase III clinical trial of “Recombinant Human Hepatocyte Growth Factor Naked Plasmid Injection” (code-named NL003), specifically for the indication of rest pain in patients with severe lower-limb ischemic disease (CLI). The ulcer indication for this trial had already been completed ahead of schedule on June 7, 2023. With the completion of enrollment for the rest-pain indication—reaching the target of 300 subjects—the Phase III clinical trial of NL003 has now fully achieved its planned enrollment target, marking a significant milestone in the development program and representing a crucial step toward product registration.

21

2023-11

The company has been approved to establish the Beijing Postdoctoral Innovation and Practice Base.

发布时间：2023-11-21

Today, the Beijing Municipal Bureau of Human Resources and Social Security organized and held the “Conference on Mobilizing Postdoctoral Talent to Advance China’s Modernization,” and simultaneously released the list of enterprises newly approved to establish postdoctoral workstations this year. Our company has successfully been approved to set up a Beijing Postdoctoral Innovation and Practice Base and has received the official plaque, providing a new pathway for the company to attract high-level young talents.

07

2023-11

Good News: Our company’s Sodium Quinolinate Eye Drops have won the bid in the 9th Round of National Centralized Procurement.

发布时间：2023-11-07

On the morning of November 6, 2023, the ninth round of national centralized drug procurement was opened in Shanghai, and our company’s ophthalmic product, Diquafos Sodium Eye Drops (Hui Liang@), successfully won the bid. This round of centralized procurement involved 42 pharmaceutical products, covering 11 major therapeutic categories including hypertension, diabetes, anti-tumor, anti-infective, gastrointestinal diseases, and cardiovascular and cerebrovascular diseases. Among them, a total of seven companies participated in the bidding for the ophthalmic product Diquafos Sodium Eye Drops, including the original research manufacturer Santen, as well as well-known domestic pharmaceutical companies such as Yangtze River Pharmaceutical Group, Guangdong ZhongSheng, Qilu Pharmaceutical, Shenyang Xingqi, and Chengdu Shengdi. Upon announcement of the results, our company secured the bid at fourth place and was selected to supply the following regions: Shandong, Tianjin, Gansu, Inner Mongolia, Hainan, and Guizhou.

26

2023-09

NORTHLAND successfully passed the GMP compliance inspection.

发布时间：2023-09-26

On September 26, 2023, our company received the “Notice of Pharmaceutical GMP Compliance Inspection Results” issued by the Beijing Municipal Administration for Drug Supervision. Our 0.1% (5ml:5mg) Sodium Hyaluronate Eye Drops product has successfully passed the pharmaceutical GMP compliance inspection. This product is the first one our company has brought to market under the MAH (Marketing Authorization Holder) system, having undergone on-site verification as the MAH itself. This milestone marks the official launch of our company’s commercialization efforts.

10

2023-08

Another NORTHLAND eye drop product, "Diquafosol Sodium," has been approved.

发布时间：2023-08-10

Recently, our company’s ocular formulation, “Diquafosol Sodium Eye Drops,” has received the “Drug Registration Certificate” approved and issued by the National Medical Products Administration. The approval number is: National Drug Approval No. H20234037. This product is classified as a Class 4 chemical drug and comes in a specification of 3% (5 ml: 150 mg). This marks our company’s second ophthalmic product to be launched on the market, following the approval we obtained in May for Sodium Hyaluronate Eye Drops 0.1% (5 ml: 5 mg). Meanwhile, the active pharmaceutical ingredient “Diquafosol Sodium,” which our company is also responsible for registering, has also passed the review and been registered under the filing number: Y20210000404.

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.

These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.

Friendly Links: Baidu | NORTHLAND

NORTHLAND

Contact Information

Address: Room A406, Zhongguancun Biomedical Park, No. 5 Kaituo Road, Shangdi, Haidian District, Beijing

Hotline: +86 010-82890893

Email: northland@northland-bio.com

Website: www.northland-bio.com

Complaints Reporting Hotline: +86 010-82890893-8031

Complaints Reporting Email: pv@northland-bio.com

Follow Us

Northland is an innovative biopharmaceutical company specializing in the R&D, manufacturing and sales of gene therapy drugs, recombinant protein drugs and ophthalmic medications.

WeChat Mini Program

Web site

WeChat Official Account

NL-BIO

Scientific Research on Lower Limb Ischemia

NL003

Myocardial Infarction Scientific Research

NL005

Business license

Powered by 300.cn  Privacy Policy